Abbott Expands Rashfree™ Portfolio with New Eva Cream and Spray for Women and Elderly Adults

IMT News Desk
IMT News Desk
· 2 min read
Abbott extends its Rashfree range with Eva Cream and Spray, offering gentle, effective rash and chafing relief for women and elderly adults in India.

Abbott has expanded its Rashfree™ portfolio with the launch of Rashfree™ Eva Cream and Rashfree™ Spray, extending the brand’s trusted expertise beyond baby care to address the everyday skin needs of women and elderly adults. The new products are designed to help soothe, protect and care for skin irritation caused by friction, sweat, moisture and sensitivity, particularly in India’s hot and humid climate.

Rashfree™ Eva Cream is specially formulated to help relieve rashes and chafing in sensitive areas, making it suitable for women who frequently experience discomfort in high-friction zones due to factors such as sweat, hormonal changes, active lifestyles, tight clothing and prolonged use of personal hygiene products. Rashfree™ Spray offers a convenient, touch-free way to care for irritated skin, helping adults, especially those using diapers due to incontinence or limited mobility, gently manage discomfort and maintain hygiene. Together, Rashfree™ Eva Cream and Rashfree™ Spray aim to provide simple, effective care for diaper-related and everyday irritation.

Abbott notes that many people currently rely on home remedies or quick fixes that may not provide lasting relief. Rashfree™ Eva Cream and Rashfree™ Spray have been developed as more reliable and targeted solutions, with each product tailored to different skin needs, whether everyday irritation in women or diaper-related discomfort in adults. The formulations are designed to help protect the skin, keep it hydrated, soothe irritation and support the natural healing process, while remaining gentle and easy to use in daily routines.

Through its expanded Rashfree™ portfolio, Abbott aims to elevate skin care with solutions that enhance comfort, restore confidence and support skin health across life stages. “There is a clear and growing need for simple, effective solutions to address everyday skin concerns that are often under-recognized yet impact comfort and quality of life. With this launch, we aim to bridge this gap by offering convenient, easy-to-use solutions that support both individuals and caregivers in maintaining healthy skin,” said V. Ramanathan, Managing Director & General Manager, Abbott’s Primary Care business in India.

Commenting on the medical need, Ankith Rai, Associate Director, Medical Affairs, Abbott India, added, “Skin irritation caused by moisture and friction is common, particularly in India’s climate, and can affect both physical comfort and confidence. Using appropriate, gentle care can help soothe irritation, protect the skin barrier, and support overall skin health.”

Read Next

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director
News
July 14, 2026

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director

Prime Minister Narendra Modi will dedicate several key healthcare infrastructure projects to the nation on July 17, according to PGIMER Director Dr Vivek Lal. The projects include the Advanced Mother and Child Centre, the Advanced Neurosciences Centre and a new Critical Care Block, all of which are expected to strengthen tertiary care services and expand […]
Article by: IMT News Desk
OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars
News
July 14, 2026

OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars

OneSource Specialty Pharma Limited and Formycon AG have announced a strategic manufacturing partnership for biosimilars, bringing together Formycon’s biosimilar development expertise and OneSource’s integrated biologics manufacturing capabilities to support global markets. Under the agreement, OneSource will serve as a strategic manufacturing partner for Formycon and provide both drug substance and drug product manufacturing from its […]
Article by: IMT News Desk
FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi
News
July 14, 2026

FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi

The U.S. Food and Drug Administration has approved an at-home starting dose of Eisai and Biogen’s Alzheimer’s drug Leqembi, allowing some patients to begin treatment with injections administered by themselves or a caregiver. The decision expands access to the drug’s subcutaneous formulation, which can now be used as a starter dose rather than only after […]
Article by: IMT News Desk
Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition
News
July 14, 2026

Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition

Emcure Pharmaceuticals Limited has announced the consolidation of its shareholding in biopharma subsidiary Gennova Biopharmaceuticals Limited, alongside a leadership transition, as it sharpens its focus on biologics and biosimilars. The company is acquiring the entire 12.05% minority stake in Gennova held by Dr Sanjay Singh and others, taking its ownership to 100% and making Gennova […]
Article by: IMT News Desk